TRABD
Overview
TRABD (TraB domain-containing protein) is the 5’ fusion partner in TRABD-DDR2 gene fusions identified in head and neck squamous cell carcinoma (HNSC). This fusion creates a promoter swap that drives DDR2 overexpression, proposing DDR2 as a druggable target with dasatinib. TRABD itself has no established oncogenic function.
Alterations observed in the corpus
- Identified as the 5’ partner in TRABD-DDR2 fusion in an HNSC sample; this promoter-swap fusion drives DDR2 overexpression and has been proposed as a candidate for dasatinib therapy following von Massenhausen et al. 2016 PMID:29617662
Cancer types (linked)
- Head and neck squamous cell carcinoma (HNSC): TRABD-DDR2 promoter-swap fusion identified PMID:29617662
Co-occurrence and mutual exclusivity
Therapeutic relevance
- The TRABD-DDR2 fusion drives DDR2 overexpression; dasatinib has been proposed as a targeted therapy based on DDR2 inhibition PMID:29617662
Open questions
Sources
This page was processed by crosslinker on 2026-05-15.